RxDoctor Payments Data

Carlos Ventura, MD

Internal Medicine · Kettering, OHNPI 1174842884

Payments from drug & device makers

$2,553in general payments, 2019–2025

Across 116 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$473
  • Novo Nordisk$395
  • AstraZeneca$370
  • Johnson & Johnson$365
  • Abbott$302
  • Amgen$218
  • plus $431 from 7 others

What the payments were for

  • Food & beverage$2,52799%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,553 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$144,098
Medicare patients
256
Services billed
1,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$93,734
OzempicSemaglutide48$82,031
TrulicityDulaglutide37$60,101
FarxigaDapagliflozin Propanediol51$49,936
JanuviaSitagliptin Phosphate29$34,896
Tresiba Flextouch U-100Insulin Degludec21$29,960
EntrestoSacubitril/Valsartan20$29,911
JardianceEmpagliflozin24$26,540
MyrbetriqMirabegron35$24,246
RybelsusSemaglutide12$17,315
XareltoRivaroxaban18$15,398
Xigduo XrDapaglifloz Propaned/Metformin17$15,322
Spiriva RespimatTiotropium Bromide17$8,820
Breo ElliptaFluticasone/Vilanterol12$7,850
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$4,793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$395$99,34760 claims
PfizerEliquis$72$93,73477 claims
Lilly USA, LLCTrulicity$143$60,10137 claims
AstraZenecaFarxiga$370$49,93651 claims
Boehringer IngelheimJardiance, Spiriva Respimat$473$35,36041 claims
MerckJanuvia$124$34,89629 claims
Johnson & JohnsonXarelto$365$15,39818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →